$71.74
-0.26 (-0.36%)
Celgene Corp (NASDAQ:CELG)
CAPS Rating:
A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.
RSS Headlines
Fool UK